Cointime

Geron

company

About

Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,

  • 101 - 250

Highlights

Total Funding Amount
$125M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$125M
Industries
Biopharma,Biotechnology,Health Diagnostics,Pharmaceutical
Founded date
Aug 28, 1990
Number Of Employee
101 - 250
Operating Status
Active

Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is a product candidate in clinical development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$125M
Geron has raised a total of $125M in funding over 2 rounds. Their latest funding was raised on Jun 30, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 30, 2022 Post-IPO Debt $125M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Geron is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital — Post-IPO Debt
Cointime
เนื้อหา
บริษัท